Loading…
Aclarion, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ACON.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $4.60 | $1,302.48 | $28,944.00 | $83,937.60 | |
| P/S | 221.1x | 138.6x | 16589.2x | 303.6x | 75.0x |
| P/B | 2.0x | 0.8x | 781.9x | — | 2.0x |
| EPS | -$13.61 | -$7,478.90 | -$79,782.00 | -$177,372.45 | |
| Profit margin | -10623.16% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CLGNCollPlant Biotechnologies Ltd | $0.36 | — | 1.1x | — | -151.99% | $6.77M |
| INBSIntelligent Bio Solutions Inc | $2.36 | — | 1.2x | — | -307.69% | $7.14M |
| BOLTBolt Biotherapeutics, Inc. | $3.71 | — | 0.6x | — | -111.65% | $7.15M |
| CURXCuranex Pharmaceuticals Inc | $4.56 |
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Company description provided by Yahoo Finance.
| -9551.87% |
| -15293.78% |
| -6513.41% |
| -11694.45% |
| ROE | -317.55% | -56.36% | -720.88% | — | -317.55% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.4x |
| — |
| -411.08% |
| $7.15M |
| DRMADermata Therapeutics, Inc. | $1.34 | — | 1.5x | — | -183.89% | $6.64M |
| BMRABiomerica Inc | $2.14 | — | 2.0x | — | -94.32% | $6.61M |